JP2019524888A - 血液がんの治療のためのPPARγアゴニスト - Google Patents

血液がんの治療のためのPPARγアゴニスト Download PDF

Info

Publication number
JP2019524888A
JP2019524888A JP2019530367A JP2019530367A JP2019524888A JP 2019524888 A JP2019524888 A JP 2019524888A JP 2019530367 A JP2019530367 A JP 2019530367A JP 2019530367 A JP2019530367 A JP 2019530367A JP 2019524888 A JP2019524888 A JP 2019524888A
Authority
JP
Japan
Prior art keywords
leukemia
subject
effective amount
therapeutically effective
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524888A5 (enExample
Inventor
クリストス マントゾロス
クリストス マントゾロス
Original Assignee
インテクリン セラピューティクス インコーポレイテッド
インテクリン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテクリン セラピューティクス インコーポレイテッド, インテクリン セラピューティクス インコーポレイテッド filed Critical インテクリン セラピューティクス インコーポレイテッド
Publication of JP2019524888A publication Critical patent/JP2019524888A/ja
Publication of JP2019524888A5 publication Critical patent/JP2019524888A5/ja
Priority to JP2022091309A priority Critical patent/JP2022116304A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019530367A 2016-08-18 2017-08-18 血液がんの治療のためのPPARγアゴニスト Pending JP2019524888A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022091309A JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのPPARγアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
US62/376,749 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022091309A Division JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのPPARγアゴニスト

Publications (2)

Publication Number Publication Date
JP2019524888A true JP2019524888A (ja) 2019-09-05
JP2019524888A5 JP2019524888A5 (enExample) 2020-10-01

Family

ID=61197183

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530367A Pending JP2019524888A (ja) 2016-08-18 2017-08-18 血液がんの治療のためのPPARγアゴニスト
JP2022091309A Withdrawn JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのPPARγアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022091309A Withdrawn JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのPPARγアゴニスト

Country Status (12)

Country Link
US (1) US20210379049A1 (enExample)
EP (1) EP3500268A4 (enExample)
JP (2) JP2019524888A (enExample)
KR (1) KR20190064573A (enExample)
CN (1) CN110461329A (enExample)
AU (1) AU2017313839A1 (enExample)
BR (1) BR112019003130A2 (enExample)
CA (1) CA3034258A1 (enExample)
EA (1) EA201990512A1 (enExample)
MX (1) MX2019001979A (enExample)
SG (2) SG10202101501PA (enExample)
WO (1) WO2018035446A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256208A (ja) * 1999-03-09 2000-09-19 Univ Osaka 抗炎症剤、単球系細胞の増殖抑制剤
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505944QA (en) * 2013-01-30 2015-08-28 Intekrin Therapeutics Inc PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
PL3468604T3 (pl) * 2016-06-08 2021-07-12 Support-Venture Gmbh Kombinacje farmaceutyczne do leczenia nowotworu złośliwego

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256208A (ja) * 1999-03-09 2000-09-19 Univ Osaka 抗炎症剤、単球系細胞の増殖抑制剤
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN HEMATOLOGY, vol. 2009, JPN6021020544, 2009, pages 6 pages, ISSN: 0004699789 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, JPN6021020555, 2013, pages 979 - 992, ISSN: 0004518948 *
BLOOD, vol. 113(16), JPN6021020549, 2009, pages 3655 - 3665, ISSN: 0004518944 *
BLOOD, vol. 118(22), JPN6021020543, 2011, pages 5872 - 5882, ISSN: 0004699788 *
CANCER CAUSES CONTROL, vol. 20, JPN6021020554, 2009, pages 193 - 199, ISSN: 0004518947 *
CLINICAL IMMUNOLOGY, vol. 113, JPN6021020551, 2004, pages 203 - 213, ISSN: 0004518945 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 58, JPN6021020546, 2006, pages 1 - 14, ISSN: 0004518942 *
DIABETES CARE, vol. 37, JPN6021020540, 2014, pages 1918 - 1923, ISSN: 0004699786 *
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 755, JPN6021020557, 2015, pages 50 - 57, ISSN: 0004518949 *
HTTPS://PROFESSIONAL.DIABETES.ORG/ABSTRACT/T0903131-SELECTIVE-MODULATOR-PPAR-GAMMA-ACTIVITY-INCREASE, JPN6021020541, 2004, ISSN: 0004699787 *
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 83(3), JPN6021020552, 2006, pages 254 - 258, ISSN: 0004518946 *
LIFE SCIENCES, vol. 135, JPN6021020547, 2015, pages 55 - 67, ISSN: 0004518943 *
PPAR RESEARCH, vol. 2008, JPN6021020537, 2008, pages 9 pages, ISSN: 0004699785 *

Also Published As

Publication number Publication date
EP3500268A4 (en) 2020-04-15
EP3500268A1 (en) 2019-06-26
KR20190064573A (ko) 2019-06-10
US20210379049A1 (en) 2021-12-09
CA3034258A1 (en) 2018-02-22
BR112019003130A2 (pt) 2019-05-21
MX2019001979A (es) 2019-09-19
SG10202101501PA (en) 2021-03-30
CN110461329A (zh) 2019-11-15
SG11201901320WA (en) 2019-03-28
WO2018035446A1 (en) 2018-02-22
EA201990512A1 (ru) 2019-08-30
JP2022116304A (ja) 2022-08-09
AU2017313839A1 (en) 2019-03-07

Similar Documents

Publication Publication Date Title
JP2022116304A (ja) 血液がんの治療のためのPPARγアゴニスト
EP3730140B1 (en) Tradipitant for use in treating nausea or vomiting
JP2024530310A (ja) T細胞リンパ腫治療薬の調製におけるezh2阻害剤の使用
CN102908347A (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
JP6862404B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
JP2024501471A5 (enExample)
JP2024177232A (ja) 非アルコール性脂肪性肝疾患の予防及び治療薬
CN113908159A (zh) 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
EP3793543A1 (en) Methods and compositions for treatment of alzheimer's disease
EP3866804A1 (en) Combinations for immune-modulation in cancer treatment
Bose et al. New concepts of treatment for patients with myelofibrosis
JP2018526440A (ja) 免疫系を刺激するためのインドール化合物の使用
JP2019524888A5 (enExample)
JP2020515639A5 (enExample)
CA3005961C (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
EP3956342A1 (en) Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
KR20240158980A (ko) 유기 화합물
WO2022161364A1 (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
KR20220124739A (ko) 암의 치료를 위한 병용 요법
MD4844C1 (ro) Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
KR20200067859A (ko) Ccr3-억제제를 사용한 소양증, 건조증, 및 관련 질환을 치료하기 위한 방법 및 조성물
RU2822394C1 (ru) Способы лечения
WO2020069008A1 (en) Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
KR20230042065A (ko) 테모졸로마이드와 돌연변이 idh1 효소 억제제의 조합 의약
HK1248552B (en) Method of treatment with tradipitant

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220207